XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Net loss $ (2,670,705) $ (15,116,470)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,455,796 2,702,388
Stock compensation 544,376 885,029
Gain on sale of real estate assets, net (4,777,327) (2,829,998)
Impairment of goodwill and real estate assets 4,344,332 196,793
Amortization of financing costs 137,749 214,071
Amortization of below-market leases (2,266) (2,487)
Straight-line rent adjustment (27,948) (95,602)
Changes in operating assets and liabilities:    
Other assets 36,322 588,866
Accounts payable and accrued liabilities (397,856) (877,612)
Accrued real estate taxes (839,159) (855,233)
Net cash used in operating activities (1,012,227) (1,301,028)
Cash flows from investing activities:    
Real estate acquisitions (9,444,465) (5,740,918)
Additions to buildings and tenant improvements (741,071) (1,417,990)
Proceeds from sale of marketable securities 13,990 60,467
Proceeds from sales of real estate, net 21,544,343 20,058,923
Net cash provided by investing activities 11,372,797 12,960,482
Cash flows from financing activities:    
Proceeds from mortgage notes payable, net of issuance costs 6,592,396 10,663,089
Payment of debt issuance costs (247,882) (182,798)
Repayment of mortgage notes payable (14,014,678) (17,282,249)
Payment of deferred offering costs 0 (349,589)
Distributions to noncontrolling interests (433,804) (2,806,333)
Contributions from noncontrolling interests 0 200,000
Issuance of Series D Preferred Stock, net of offering costs 0 1,195,855
Dividends paid to Series D Preferred Stockholders (1,153,671) (1,065,363)
Net cash used in financing activities (11,111,977) (9,635,001)
Net (decrease) increase in cash equivalents and restricted cash (751,407) 2,024,453
Cash, cash equivalents and restricted cash - beginning of period 8,036,496 6,510,428
Cash, cash equivalents and restricted cash - end of period 7,285,089 8,534,881
Supplemental disclosure of cash flow information:    
Income taxes paid 46,511 0
Non-cash financing activities:    
Paid building and tenant improvements from prior year (207,847) (295,567)
Unpaid building and tenant improvements 176,307 91,513
Dividends payable - Series D Preferred Stock 190,393 195,310
Mortgage Notes [Member]    
Supplemental disclosure of cash flow information:    
Interest paid-mortgage notes payable 2,998,056 2,810,393
Common Class A [Member]    
Cash flows from financing activities:    
Repurchase of Series A Common Stock, at cost (1,526,551) (7,613)
Series D Preferred Stock [Member]    
Cash flows from financing activities:    
Repurchase of Series D Preferred Stock, at cost (327,787) 0
Conduit Pharmaceuticals Inc [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Net loss (gain) in fair value marketable securities 184,459 13,888,667
All Other Than Conduit [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Net loss (gain) in fair value marketable securities $ 0 $ 560